8:02 am Merrimack Pharma announced Phase 1 results from a clinical pilot study demonstrating that ferumoxytol, an iron oxide nanoparticle, was well tolerated when used as a tumor contrast agent prior to MM-398 treatment.

8:02 am Merrimack Pharma announced Phase 1 results from a clinical pilot study demonstrating that ferumoxytol, an iron oxide nanoparticle, was well tolerated when used as a tumor contrast agent prior to MM-398 treatment.

more

View todays social media effects on MACK

View the latest stocks trending across Twitter. Click to view dashboard

See who Merrimack is hiring next, click here to view

Share this post